Natpar for Hypoparathyroidism Gets Green Light in Europe Natpar for Hypoparathyroidism Gets Green Light in Europe

The first replacement hormone therapy for chronic hypoparathyroidism that cannot be treated with standard therapy of calcium and vitamin D, a rare disease, has passed the first hurdle for approval in the EU.International Approvals
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news